Weight LossMetabolicPrices may be stale · 28d ago

Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics. It was approved in China in June 2025 for weight management and in September 2025 for type 2 diabetes. It is not approved in the United States or Europe.

Lowest cost / mg: $5.75/mg; at Peptide Labs Inc
Suppliers listed: 6
In stock: 7 of 10; listings
COA reports: 9

Jump to

Overview Supplier Listings Benefits Evidence Interactions FAQ

Supplier listings

Compare Mazdutide prices.

Form

Show prices as

Size

10 listings · Mazdutide

Peptide Labs IncLowest $/mg
In stock10 mg · 10 vialsseen 7w ago
$517.50
$575.00$5.18/mg-10%
PEPLOOKUP
Alpha Peptides
In stock10mgseen 7w ago
$59.79
$66.43$5.98/mg-10%
peplookup
Disguised Alpha
In stock5mgseen 4w ago
$71.99
$79.99$14.40/mg-10%
PEPLOOKUP
Sparta Labs
In stock5mgseen 7w ago
$85.00
$100.00$17.00/mg-15%
PEPLOOKUP
Pivot Labs
In stock10mgseen 7w ago
$148.75
$175.00$14.88/mg-15%
adamdan
Biologix Labs
Out of stock5mgseen 5w ago
$45.89
$50.99$9.18/mg-10%
PEPLOOKUP

Overview

What is Mazdutide?

Weight Management
Glycemic Control
Dual Mechanism
Metabolic Health

What the research reports

Reported benefits of Mazdutide

Outcomes described across the published Mazdutide literature and ongoing study. Read each as research context rather than a promised personal result.

01
Dual GLP-1 and glucagon action
Pairs GLP-1 appetite suppression with glucagon driven energy expenditure, a mechanism distinct from GLP-1 only agonists. Reported in research settings.
02
Weight loss results in trials
GLORY-1 reported 12 to 15 percent weight reduction at 4 and 6 mg over 48 weeks against roughly 0.5 percent on placebo in Chinese adults. Reported in research settings.
03
Higher dose weight outcomes
GLORY-2 tested 9 mg and reported up to 20.1 percent weight loss over a year in Chinese adults with obesity and no type 2 diabetes. Reported in research settings.
04
Glycaemic control outcomes
Phase 2 and 3 diabetes work reported HbA1c reductions of 1.41 to 1.67 percent alongside weight loss of up to 7.1 percent. Reported in research settings.
05
Comparator trial performance
A phase 3 trial reported superiority to dulaglutide on both HbA1c and body weight in 731 Chinese adults with type 2 diabetes. Reported in research settings.

Clinical evidence

Clinical evidence for Mazdutide

The published Mazdutide record, labeled by strength so you can see what is settled and what is still emerging.

GLORY-1 phase 3 obesity trial

A 2025 NEJM phase 3 trial in 610 Chinese adults reported 11 to 14 percent body weight reduction on 4 to 6 mg against 0.3 percent on placebo over 48 weeks. Reported in the cited paper.

Source

Dulaglutide comparison results

A 2025 Nature phase 3 trial in 731 Chinese adults with type 2 diabetes reported superiority to dulaglutide on both HbA1c and body weight over 28 weeks. Reported in the cited paper.

Source

Phase 2 diabetes safety trial

A 2025 NEJM phase 3 trial in 610 Chinese adults reported 12 to 15 percent body weight reduction on 4 to 6 mg against roughly 0.5 percent on placebo over 48 weeks. Reported in the cited paper.

Source

Interactions

How Mazdutide pairs with other peptides

Semaglutide: Overlapping GLP-1 activity with no trial support for combining the two agents together. Confidence: emerging.
Tirzepatide: Both are incretin based agonists. Stacking adds gastrointestinal burden without established benefit.
Insulin therapy: The glucagon component affects hepatic glucose output, so glucose monitoring matters more here.
Sulfonylureas: Combined glucose lowering raises hypoglycaemia risk and warrants a prescribing review first.

Questions

Frequently asked questions.

What is Mazdutide?

Mazdutide is a dual GCGR/GLP-1 receptor agonist developed by Innovent Biologics, approved in China for weight management and type 2 diabetes. It belongs to the same class of GLP-1-based metabolic therapies as tirzepatide and retatrutide.

How does Mazdutide work?

Mazdutide activates both the glucagon receptor and the GLP-1 receptor, a dual mechanism studied for its combined effects on appetite regulation, glucose control and energy expenditure.

Mazdutide vs Retatrutide: what's the difference?

Both are being studied as multi-receptor agonists for metabolic research, but Mazdutide is a dual GCGR/GLP-1 agonist while Retatrutide is a triple agonist (GIP/GLP-1/glucagon). They target overlapping but not identical receptor pathways.

Mazdutide vs Tirzepatide: what's the difference?

Tirzepatide is a dual GIP/GLP-1 agonist, while Mazdutide is a dual GCGR/GLP-1 agonist. The receptor pairing differs, which is why researchers compare their mechanisms rather than treating them as interchangeable.

Is Mazdutide for research use only?

PepLookup lists Mazdutide for research and price-comparison purposes only. We do not provide dosing, route or administration guidance. Consult the primary literature and your supplier's documentation before any research use.

Mazdutide

Lowest cost / mg

$5.75/mg

at Peptide Labs Inc

Suppliers listed

In stock

7 of 10

listings

COA reports

What is Mazdutide?

Weight Management

Glycemic Control

Dual Mechanism

Metabolic Health

Reported benefits of Mazdutide

Outcomes described across the published Mazdutide literature and ongoing study. Read each as research context rather than a promised personal result.

Dual GLP-1 and glucagon action

Pairs GLP-1 appetite suppression with glucagon driven energy expenditure, a mechanism distinct from GLP-1 only agonists. Reported in research settings.

Weight loss results in trials

GLORY-1 reported 12 to 15 percent weight reduction at 4 and 6 mg over 48 weeks against roughly 0.5 percent on placebo in Chinese adults. Reported in research settings.

Higher dose weight outcomes

GLORY-2 tested 9 mg and reported up to 20.1 percent weight loss over a year in Chinese adults with obesity and no type 2 diabetes. Reported in research settings.

Glycaemic control outcomes

Phase 2 and 3 diabetes work reported HbA1c reductions of 1.41 to 1.67 percent alongside weight loss of up to 7.1 percent. Reported in research settings.

Comparator trial performance

A phase 3 trial reported superiority to dulaglutide on both HbA1c and body weight in 731 Chinese adults with type 2 diabetes. Reported in research settings.

Clinical evidence for Mazdutide

The published Mazdutide record, labeled by strength so you can see what is settled and what is still emerging.

GLORY-1 phase 3 obesity trial

A 2025 NEJM phase 3 trial in 610 Chinese adults reported 11 to 14 percent body weight reduction on 4 to 6 mg against 0.3 percent on placebo over 48 weeks. Reported in the cited paper.

Source

Dulaglutide comparison results

A 2025 Nature phase 3 trial in 731 Chinese adults with type 2 diabetes reported superiority to dulaglutide on both HbA1c and body weight over 28 weeks. Reported in the cited paper.

Source

Phase 2 diabetes safety trial

A 2025 NEJM phase 3 trial in 610 Chinese adults reported 12 to 15 percent body weight reduction on 4 to 6 mg against roughly 0.5 percent on placebo over 48 weeks. Reported in the cited paper.

Source

How Mazdutide pairs with other peptides

Semaglutide

Overlapping GLP-1 activity with no trial support for combining the two agents together. Confidence: emerging.

Tirzepatide

Both are incretin based agonists. Stacking adds gastrointestinal burden without established benefit.

Insulin therapy

The glucagon component affects hepatic glucose output, so glucose monitoring matters more here.

Sulfonylureas

Combined glucose lowering raises hypoglycaemia risk and warrants a prescribing review first.